For Q1 FY2026 (ended March 31, 2026), Esperion reported revenue of $80.1 million, up 23.2% year-over-year. Net loss was $25.2 million, improving 37.7% from the prior year. Operating loss narrowed to $6.6 million, a 70.2% improvement. Diluted EPS was -$0.10, compared to -$0.21 in the prior year. Cash and cash equivalents stood at $156.2 million, while stockholders' equity was negative $307.9 million.
•Revenue increased 23.2% YoY to $80.1 million.
•Net loss improved 37.7% to $25.2 million.
•Operating loss narrowed 70.2% to $6.6 million.
•Cash balance was $156.2 million at quarter end.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Esperion Therapeutics, Inc., a biopharmaceutical company develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to.
Its portfolio also includes Otsuka Pharmaceutical Co., Ltd, and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. Incorporated in 2008, the company is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for patients with elevated low-density lipoprotein cholesterol (LDL-C) in the United States. Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are oral, once-daily, non-statin medicines for treating primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or cardiovascular disease who need additional LDL-C lowering. The company also offers NILEMDO, an ATP Citrate Lyase inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors, and NUSTENDI, a bempedoic acid and ezetimibe tablet for elevated LDL-C. Esperion has license and collaboration agreements with Daiichi Sankyo Co. Ltd, Otsuka Pharmaceutical Co., Ltd, and Daiichi Sankyo Europe GmbH.
Where is Esperion Therapeutics (ESPR) listed and in which currency?
Esperion Therapeutics, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ESPR. The company's financials are reported in US Dollars (USD), as it is headquartered in the United States. The exchange is a major US stock exchange, providing liquidity and visibility for the company's shares.
What sector and industry does Esperion Therapeutics (ESPR) operate in?
Esperion Therapeutics operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This industry includes companies that develop and manufacture specialty pharmaceutical products, often focusing on niche therapeutic areas. Esperion's focus on cholesterol-lowering medications aligns with the specialty drug manufacturing segment, as it develops non-statin treatments for patients with elevated LDL-C who may not achieve adequate results with traditional statins.
Where is Esperion Therapeutics (ESPR) headquartered and what markets does it serve?
Esperion Therapeutics, Inc. is headquartered in Ann Arbor, Michigan, United States. The company primarily serves the US market, as indicated by its description summary focusing on the commercialization of medicines for patients in the United States. However, through its license and collaboration agreements with Daiichi Sankyo Europe GmbH and other partners, it may have a presence in European markets as well. The company was originally founded as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics in May 2008.
How does Esperion Therapeutics (ESPR) generate revenue?
Esperion Therapeutics generates revenue primarily through the commercialization of its marketed products: NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI. These are oral, once-daily non-statin medicines for lowering LDL-C in patients with primary hyperlipidemia, heterozygous familial hypercholesterolemia, or cardiovascular disease. The company also earns revenue from license and collaboration agreements with partners such as Daiichi Sankyo Co. Ltd, Otsuka Pharmaceutical Co., Ltd, and Daiichi Sankyo Europe GmbH. These agreements likely involve milestone payments, royalties, or profit-sharing arrangements for the development and commercialization of its products in various regions.